Peptide & Compound Guide
At a glance
| Compound | Semaglutide |
|---|---|
| Type | GLP-1 receptor agonist peptide medicine |
| U.S. regulatory context | FDA-approved active ingredient in prescription products for specific indications |
| Evidence level | Established clinical evidence for approved uses |
| Research area | Type 2 diabetes, obesity, cardiovascular-risk reduction in defined populations |
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as the active ingredient in several FDA-approved prescription products. Brand, dose, formulation and approved indication matter: the same active ingredient can appear in products approved for different uses.
What does the research examine?
Clinical research has evaluated glycemic control, body weight, cardiovascular outcomes and other metabolic endpoints. Evidence from approved semaglutide products should not automatically be generalized to unapproved formulations.
What has not been established?
Mechanism, biomarker changes, animal findings and early clinical signals are not the same as proof that a compound safely improves meaningful health outcomes. Claims should be matched to the type, size and quality of evidence available.
Safety and regulatory context
Use only under appropriate medical supervision. Product labeling includes important contraindications, warnings and adverse-effect information.
Related: Semaglutide vs. Tirzepatide
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.